WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) announced that Shai N. Gozani, M.D.,
Ph.D., President and CEO, will participate in a panel titled "Roadmap to
FDA Approval" on Tuesday, January 5 at the 2016 CES Event in Las Vegas.
The panel moderator is Alfred
Poor, Editor of Health Tech Insider. Dr. Gozani will be joined by
other industry thought leaders including Dr. Nick van Terheyden, M.D.,
Chief Medical Officer at Dell, Bakul Patel, Associate Center Director
for Digital Health at FDA, and Beth Bierman, Partner at Morgan Lewis &
Bockius. The panel will address the opportunities and challenges of
regulated wearable medical devices and apps. CES is the largest consumer
technology event and has served as the launch pad for innovators and
breakthrough technologies for almost 50 years. CES attracts global
business leaders and pioneering thinkers to a forum where the industry's
most relevant issues are addressed.
"If wearable technology is going to achieve its tremendous potential it
must move beyond wellness to tackling fundamental health problems such
as chronic pain, diabetes, and heart disease. This necessarily implies
regulation by the FDA," said Dr. Gozani. "I hope this panel will start
to demystify the regulatory process and encourage technology companies
to embrace the opportunity of consumer medical technology. I believe
that NeuroMetrix has some important experiences to share because of our
15 years as a traditional medical device company prior to transitioning
into consumer health."
CES attendees will have an opportunity to learn about Quell®,
the NeuroMetrix wearable device for treating chronic pain. The Company
will offer a first glimpse of the latest generation of Quell technology
at Booth # 73313 in the Digital Health section of CES.
Quell utilizes NeuroMetrix's patented neurostimulation technology to
provide widespread relief from chronic pain. The advanced wearable
device is lightweight and can be worn during the day while active, and
at night while sleeping. It has been cleared by the FDA for treatment of
chronic pain without a prescription. In a recent study, 81% of Quell
users reported an improvement in their chronic pain. Quell includes a
smartphone app that tracks and personalizes their pain therapy. It is
available for purchase at QuellRelief.com,
selected retailers and healthcare professionals.
About NeuroMetrix
NeuroMetrix is an innovative healthcare company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151228005248/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
